FrancophonIA/ELRC3.0 huggingface dataset:
English: • If you notice a marked decrease in your urine output (sign of kidney problem),
Danish: • Hvis du oplever en kraftig nedsættelse af din urinproduktion (tegn på nyreproblemer)
English: What EXJADE contains
Danish: EXJADE indeholder
English: These side effects are uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people).
Danish: Visse bivirkninger kan være alvorlige og kræve omgående lægehjælp Disse bivirkninger er ikke almindelige (kan påvirke op til 1 ud af 100 patienter) eller sjældne (kan påvirke op til 1 ud af 1.000 patienter).
English: Reduction of daily dose by 10 mg/kg/day (dispersible tablet formulation), if following renal parameters are observed at two consecutive visits and cannot be attributed to other causes
Danish: Reduktion af daglig dosis med 10 mg/kg/dag (dispergible tablet), hvis følgende renale parametre er set ved to på hinanden følgende kontrolbesøg og ikke kan forklares af andre årsager
English: The majority of these patients had renal impairment, renal tubulopathy (Fanconi syndrome) or diarrhoea, or conditions where acid-base imbalance is a known complication (see section 4.4).
Danish: Hovedparten af disse patienter havde nedsat nyrefunktion, renal tubulopati (Fanconis syndrom), eller diarré, eller forhold, hvor syre-base ubalance er en kendt komplikation (se pkt.
English: This includes in particular: - other iron chelators, which must not be taken with EXJADE, - antacids (medicines used to treat heartburn) containing aluminium, which should not be taken at the same time of day as EXJADE, - ciclosporin (used to prevent the body rejecting a transplanted organ or for other conditions, such as rheumatoid arthritis or atopic dermatitis), - simvastatin (used to lower cholesterol), - certain painkillers or anti-inflammatory medicines (e.g. aspirin, ibuprofen, corticosteroids), - oral bisphosphonates (used to treat osteoporosis), - anticoagulant medicines (used to prevent or treat blood clotting), - hormonal contraceptive agents (birth control medicines), - bepridil, ergotamine (used for heart problems and migraines), - repaglinide (used to treat diabetes), - rifampicin (used to treat tuberculosis), - phenytoin, phenobarbital, carbamazepine (used to treat epilepsy), - ritonavir (used in the treatment of HIV infection), - paclitaxel (used in cancer treatment), - theophylline (used to treat respiratory diseases such as asthma), - clozapine (used to treat psychiatric disorders such as schizophrenia), - tizanidine (used as a muscle relaxant), - cholestyramine (used to lower cholesterol levels in the blood), - busulfan (used as a treatment prior to transplantation in order to destroy the original bone marrow before the transplant).
Danish: kortikosteroider), - orale bisphosphonater (bruges til behandling af osteoporose), - antikoagulerende medicin (bruges til at modvirke eller behandling af blodpropper), - hormonelle graviditetsforebyggende midler, - bepridil, ergotamin (bruges til behandling af hjerteproblemer og migræne), - repaglinid (bruges til at behandle sukkersyge), - rifampicin (bruges til at behandle tuberkulose), - phenytoin, phenobarbital, carbamazepin (bruges til at behandle epilepsi), - ritonavir (bruges i behandlingen af HIV-infektion), - paclitaxel (bruges i kræftbehandling), - theophyllin (bruges i behandlingen af lungesygdomme såsom astma), - clozapin (bruges til behandling af psykiske sygdomme såsom skizofreni), - tizanidin (virker muskelafslappende), - cholestyramin (bruges til at sænke kolesterolniveauet i blodet), - busulfan (bruges som behandling for at ødelægge den originale knoglemarv inden en transplantatation).
English: The study compared the efficacy of two different deferasirox dispersible tablet regimens (starting doses of 5 and 10 mg/kg/day, 55 patients in each arm) and of matching placebo (56 patients).
Danish: Studiet sammenlignede virkningen af to forskellige deferasirox dispergibel tabletbehandlinger (startdoser på 5 og 10 mg/kg/dag, 55 patienter i hver arm) og tilsvarende placebo (56 patienter).
English: Deafness Respiratory, thoracic and mediastinal disorders Uncommon:
Danish: Døvhed Luftveje, thorax og mediastinum Ikke almindelig:
English: Unit packs containing 28, 84 or 252 dispersible tablets and multipacks containing 294 (3 packs of 98) dispersible tablets.
Danish: Pakningerne indeholder 28, 84 eller 252 dispergible tabletter og multipakninger indeholdende 294 (3 pakker med 98) dispergible tabletter.
English: Bioavailability of deferasirox film-coated tablets was 36% greater than that with dispersible tablets.
Danish: Biotilgængeligheden af deferasirox filmovertrukne tabletter var 36% højere end den for dispergible tabletter.
English: Dose adjustments may be made in steps of 3.5 to 7 mg/kg and are to be tailored to the individual patient's response and therapeutic goals (maintenance or reduction of iron burden).
Danish: Dosisjusteringer kan gøres i trin af 3.5 til 7 mg/kg, og skal skræddersys til den enkelte patients respons og terapeutiske mål (vedligeholdelse eller reduktion af jernophobning).
English: PVC/PVDC/Aluminium blisters.
Danish: PVC/PVDC/Aluminium blisterpakninger
English: It appeared from preclinical and clinical studies that deferasirox dispersible tablets could be as active as deferoxamine when used in a dose ratio of 2:1 (i.e. a dose of deferasirox dispersible tablets that is numerically half of the deferoxamine dose).
Danish: Det fremgik af prækliniske og kliniske studier, at deferasirox dispergible tabletter kunne være ligeså aktivt som deferoxamin, når det blev administreret i en dosisratio på 2:1 (det vil sige en dosis af deferasirox dispergible tabletter, der numerisk er halvdelen af deferoxamindosis).
English: (signs of severe skin reaction, see also section 4 “Possible side effects”).
Danish: forstørrede lymfekirtler (tegn på alvorlig hudreaktion, se også punkt 4 ”Bivirkninger”).
English: 10 mg/kg/day ≥5 mg Fe/g dw or >800 µg/l
Danish: 10 mg/kg/dag ≥5 mg Fe/g tørvægt eller >800 µg/l
English: In a 5-year observational study in which 267 children aged 2 to <6 years (at enrollment) with transfusional haemosiderosis received deferasirox, there were no clinically meaningful differences in the safety and tolerability profile of Exjade in paediatric patients aged 2 to <6 years compared to the overall adult and older paediatric population, including increases in serum creatinine of >33% and above the upper limit of normal on ≥2 consecutive occasions (3.1%), and elevation of alanine aminotransferase (ALT) greater than 5 times the upper limit of normal (4.3%).
Danish: Der var ingen klinisk relevante forskelle i sikkerhed og tolerabilitet af Exjade hos pædiatriske patienter i alderen 2 til <6 år sammenlignet med den samlede population af voksne og ældre børn, inklusive stigning i serum-kreatinin på >33% og over den øvre normalgrænse ved ≥2 på hinanden følgende målinger (3,1%) samt stigning i alanin-aminotransferase (ALAT) til mere end 5 gange den øvre normalgrænse (4,3%).
English: After adjustment of the strength, the film-coated tablet formulation (360 mg strength) was equivalent to EXJADE dispersible tablets (500 mg strength) with respect to the mean area under the plasma concentration time curve (AUC) under fasting conditions.
Danish: Efter justering af styrken var den filmovertrukne tablet-formulering (360 mg) ækvivalent med EXJADE dispergible tabletter (500 mg), hvad angik det gennemsnitlige areal under tidskurven for plasmakoncentrationen (AUC) under faste.
English: Monthly monitoring of serum ferritin is recommended in order to assess the patient's response to therapy and to avoid overchelation (see section 4.2).
Danish: Månedlig monitorering af serum-ferritin anbefales for at kunne vurdere patientens respons på behandlingen og for at undgå overkelering (se pkt.
English: The availability of long-term efficacy and safety data with EXJADE dispersible tablets used at doses above 30 mg/kg is currently limited (264 patients followed for an average of 1 year after dose escalation).
Danish: Der er på nuværende tidspunkt begrænsede langtidseffekt- og sikkerhedsdata for EXJADE dispergible tabletter anvendt ved doser over 30 mg/kg (264 patienter fulgt i gennemsnitlig 1 år efter dosisoptrapning).
English: Body weight, height and sexual development
Danish: Kropsvægt, højde og seksuel udvikling Inden behandlingsstart.
English: In a clinical study using single doses of 20 mg/kg deferasirox dispersible tablets, the average exposure was increased by 16% in subjects with mild hepatic impairment (Child-Pugh Class A) and by 76% in subjects with moderate hepatic impairment (Child-Pugh Class B) compared to subjects with normal hepatic function.
Danish: I et klinisk studie, hvor der blev givet enkeltdoser på 20 mg/kg deferasirox dispergibel tabletter, var den gennemsnitlige eksponering øget med 16% hos personer med let nedsat leverfunktion (Child-Pugh Class A) og med 76% hos personer med moderat nedsat leverfunktion (Child-Pugh Class B) sammenlignet med personer med normal leverfunktion.
English: After adjustment of the strength, the granules formulation (4 x 90 mg strength) was equivalent to EXJADE dispersible tablets (500 mg strength) with respect to the mean area under the plasma concentration time curve (AUC) under fasting conditions.
Danish: Efter justering af styrken var granulat-formuleringen (4 x 90 mg) ækvivalent med EXJADE dispergible tabletter (500 mg), hvad angik det gennemsnitlige areal under tidskurven for plasmakoncentrationen (AUC) under faste.
English: Caution should be taken during chelation therapy to minimise the risk of overchelation in all patients (see section 4.4).
Danish: Der skal udvises forsigtighed hos alle patienter under kelatbehandling for at minimere risikoen for overkelering (se pkt.
English: During post-marketing experience, hepatic failure, sometimes fatal, has been reported with the deferasirox dispersible tablet formulation, especially in patients with pre-existing liver cirrhosis (see section 4.4).
Danish: Efter markedsføring er leversvigt, som nogle gange var fatalt, blevet rapporteret med den dispergible tablet-formulering, specielt hos patienter med allerede eksisterende levercirrhosis (se pkt.
English: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Danish: Bør ikke anvendes til patienter med arvelig galactoseintolerans, en særlig form af arvelig lactasemangel (Lapp Lactase deficiency) eller glucose/galactosemalabsorption.
English: Half of deferoxamine dose
Danish: Halv dosis af deferoxamin
English: Titanium dioxide (E171) Macrogol (4000)
Danish: Titandioxid (E171)
English: The availability of long-term efficacy and safety data from clinical studies conducted with EXJADE dispersible tablets used at doses above 30 mg/kg is currently limited (264 patients followed for an average of 1 year after dose escalation).
Danish: Der er på nuværende tidspunkt begrænsede langtidseffekt- og sikkerhedsdata fra udførte kliniske forsøg for EXJADE dispergible tabletter anvendt ved doser over 30 mg/kg (264 patienter fulgt i gennemsnitlig 1 år efter dosisoptrapning).
English: In a healthy volunteer study, the concomitant administration of deferasirox dispersible tablets and midazolam (a CYP3A4 probe substrate) resulted in a decrease of midazolam exposure by 17% (90% CI: 8% - 26%).
Danish: I et studie med raske frivillige, resulterede samtidig behandling med deferasirox dispergible tabletter og midazolam (et CYP3A4 test-substrat) i et fald i eksponering for midazolam på 17% (90% CI: 8% - 26%).
English: The most frequent reactions reported during chronic treatment with deferasirox dispersible tablets in adult and paediatric patients include gastrointestinal disturbances (mainly nausea, vomiting, diarrhoea or abdominal pain) and skin rash.
Danish: De hyppigste reaktioner, der er rapporteret under kronisk behandling med deferasirox dispergible tabletter hos voksne og pædiatriske patienter, inkluderer gastrointestinale forstyrrelser (hovedsageligt kvalme, opkastning, diarré eller abdominale smerter) og hududslæt.
English: Magnesium stearate Silica, colloidal anhydrous Poloxamer
Danish: Magnesiumstearat Silica, kolloid vandfri Poloxamer
English: For patients who are unable to swallow whole tablets, EXJADE film-coated tablets may be crushed and taken by sprinkling the full dose onto soft food such as yogurt or apple sauce (pureed apple).
Danish: For patienter, som ikke kan sluge hele tabletter, kan EXJADE filmovertrukne tabletter knuses og indtages ved at drysse hele dosis over blød mad, som fx yoghurt eller æblemos.
English: Daily treatment with the deferasirox dispersible tablet formulation at doses of 20 and 30 mg/kg for one year in frequently transfused adult and paediatric patients with beta-thalassaemia led to reductions in indicators of total body iron; liver iron concentration was reduced by about -0.4 and -8.9 mg Fe/g liver (biopsy dry weight (dw)) on average, respectively, and serum ferritin was reduced by about -36 and -926 µg/l on average, respectively.
Danish: Daglig behandling med den dispergible tablet-formulering med doser på 20 og 30 mg/kg i et år hos voksne og pædiatriske patienter med beta-talassæmi, som hyppigt modtog transfusioner, førte til reduktioner i indikatorer for totalt kropsjern; lever-jernkoncentrationen blev reduceret med henholdsvis omkring -0,4 og -8 mg Fe/g lever (biopsi-tørvægt) i gennemsnit, og serum-ferritin blev reduceret med henholdsvis omkring -36 og -926 µg/l i gennemsnit.
English: Multipack: 294 (3 packs of 98) dispersible tablets.
Danish: Multipakning: 294 (3 pakninger med 98) dispergible tabletter
English: Exposure was increased 2.8-fold in one subject with severe hepatic impairment (Child-Pugh Class C) (see sections 4.2 and 4.4).
Danish: Eksponeringen var øget med 2,8 gange hos en person med svært nedsat leverfunktion (Child-Pugh Class C) (se pkt.
English: The active substance is deferasirox.
Danish: Aktivt stof: Deferasirox.
English: • EXJADE 180 mg film-coated tablets are medium blue and stamped “180” on one side and
Danish: • EXJADE 180 mg filmovertrukne tabletter er mellemblå præget med ”180” på den ene side og
English: EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.
Danish: EXJADE er indiceret til behandling af kronisk jernophobning forårsaget af hyppige blodtransfusioner (≥ 7 ml/kg/måned pakkede røde blodceller) hos patienter i alderen 6 år og ældre, der har betatalassæmi major.
English: EXJADE is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) (see section 5.2).
Danish: EXJADE anbefales ikke til patienter med alvorligt nedsat leverfunktion (Child-Pugh Class C) (se pkt.
English: Early signs of acute overdose are digestive effects such as abdominal pain, diarrhoea, nausea and vomiting.
Danish: Tidlige tegn på akut overdosering er bivirkninger relateret til mave-tarm-kanalen såsom mavesmerter, diarré, kvalme og opkast.
English: During clinical studies dose-dependent increases in serum creatinine occurred in about 36% of patients, though most remained within the normal range.
Danish: Under kliniske studier forekom dosisafhængige forhøjelser af serum-kreatinin hos omkring 36% af patienterne, selvom de fleste blev inden for normalområdet.
English: The other ingredients are microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica and poloxamer.
Danish: Øvrige indholdsstoffer: mikrokrystallinsk cellulose, crospovidon, povidon, magnesiumstearat, kolloid vandfri silica og poloxamer.
English: EXJADE is supplied as dispersible tablets.
Danish: EXJADE udleveres som dispergible (opløselige) tabletter.
English: Doses above 20 mg/kg are not recommended because there is no experience with doses above this level in patients with non-transfusion-dependent thalassaemia syndromes.
Danish: Doser over 20 mg/kg anbefales ikke, da der ikke er nogen erfaring med doser over dette niveau hos patienter med ikke-transfusionsafhængige talassæmi-syndromer.
English: For deferasirox granules, a dose ratio of 3:1 can be considered (i.e. a dose of deferasirox granules that is numerically one third of the deferoxamine dose).
Danish: For deferasirox granulat kan en dosisratio på 3:1 overvejes (det vil sige at en dosis af deferasirox granulat, der numerisk er en tredjedel af deferoxamindosis).
English: Breast-feeding is not recommended during treatment with EXJADE.
Danish: Amning frarådes under behandling med EXJADE.
English: Interaction with theophylline and other agents metabolised by CYP1A2
Danish: Interaktion med theophyllin og andre lægemidler metaboliseret af CYP1A2
English: 300 (10 packs of 30) film-coated tablets
Danish: 300 (10 pakker á 30) filmovertrukne tabletter
English: Taking EXJADE at the same time each day will also help you remember when to take your tablets.
Danish: Det vil også gøre det lettere for dig at huske, hvornår du skal tage dine tabletter.
English: • Prescribers - a letter including the following dossiers: o A prescribers' guide informing about the switch between formulations in order to address the important potential risk of medication error for deferasirox o A patient's guide informing about the possibility of co-existing formulations in the EU market, and the differences concerning their administration, in order to address the important potential risk of medication error for deferasirox Additionally, prescribers and pharmacists will be informed via a specific letter regarding the timelines for removing EXJADE dispersible tablets from the EU market.
Danish: • Den ordinerende læge - et brev, som har følgende indhold: o En vejledning til den ordinerende læge, der informerer om skiftet mellem formulringer for at gøre opmærksom på den vigtige, mulige risiko for medicineringsfejl med deferasirox o En vejledning til patienten, som informerer om muligheden for samtidige formuleringer på EU-markedet og forskellen i mellem dem i forhold til deres administration.
English: In paediatric patients with non-transfusion-dependent thalassaemia syndromes, dosing should not exceed 10 mg/kg.
Danish: Hos pædiatriske patienter med ikke-transfusionsafhængige talassæmi-syndromer bør dosis ikke overstige 10 mg/kg.
English: Diarrhoea is reported more commonly in paediatric patients aged 2 to 5 years and in the elderly.
Danish: Diarré er oftere set hos pædiatriske patienter i alderen 2 til 5 år og hos ældre patienter.
English: In an iron-balance metabolic study in iron-overloaded adult thalassaemic patients, deferasirox at daily doses of 10, 20 and 40 mg/kg (dispersible tablet formulation) induced the mean net excretion of 0.119, 0.329 and 0.445 mg Fe/kg body weight/day, respectively.
Danish: I et studie i metabolisk jernbalance hos voksne talassæmipatienter med jernophobning, forårsagede daglige defereasirox-doser på 10, 20 og 40 mg/kg (dispergibel tablet-formulering) en gennemsnitlig nettoudskillelse på henholdsvis 0,119, 0,329 og 0,445 mg Fe/kg kropsvægt/dag.
English: In a healthy volunteer study, the concomitant administration of deferasirox as a moderate CYP2C8 inhibitor (30 mg/kg daily, dispersible tablet formulation), with repaglinide, a CYP2C8 substrate, given as a single dose of 0.5 mg, increased repaglinide AUC and Cmax about 2.3-fold (90% CI [2.03-2.63]) and 1.6-fold (90% CI [1.42-1.84]), respectively.
Danish: I et studie med raske frivillige blev det påvist, at administration af deferasirox, som moderat CYP2C8hæmmer (30 mg/kg daglig, dispergibel tablet-formulering) samtidig med repaglinid, et CYP2C8substrat givet som enkeltdosis på 0,5 mg, øgede AUC og Cmax for repaglinid med henholdsvis ca. 2,3 gange (90% CI [2,03-2,63]) og 1,6 gange (90% CI [1,42-1.84]).
English: 84 dispersible tablets
Danish: 84 dispergible tabletter
English: Pigmentation disorder
Danish: Pigmentforstyrrelser
English: It is recommended that serum ferritin be monitored every month to assess the patient's response to therapy and to minimise the risk of overchelation (see section 4.4).
Danish: Det anbefales, at serum-ferritin monitoreres hver måned for at kunne vurdere patientens repons på behandlingen, og for at minimere risikoen for overkelering (se pkt.
English: Unit packs containing 30 or 90 film-coated tablets or multipacks containing 300 (10 packs of 30) film-coated tablets.
Danish: Enkeltpakningerne indeholder 30 eller 90 filmovertrukne tabletter mens multipakningerne indeholder 300 (10 pakker á 30) filmovertrukne tabletter.
English: EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups: - in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (7 ml/kg/month of packed red blood cells) aged 2 to 5 years, - in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older, - in adult and paediatric patients with other anaemias aged 2 years and older.
Danish: Indikationen gælder for de følgende patientgrupper: - pædiatriske patienter med beta-talassæmi major med jernophobning forårsaget af regelmæssige blodtransfusioner ( 7 ml/kg/måned af pakkede røde blodceller) i alderen 2 til 5 år, - voksne og pædiatriske patienter med beta-talassæmi major med jernophobning forårsaget af sjældne blodtransfusioner (< 7 ml/kg/måned pakkede røde blodceller) i alderen 2 år og derover, - voksne og pædiatriske patienter med andre anæmier i alderen 2 år og derover.
English: For deferasirox film-coated tablets, a dose ratio of 3:1 can be considered (i.e. a dose of deferasirox film-coated tablets that is numerically one third of the deferoxamine dose).
Danish: For deferasirox filmovertrukne tabletter kan en dosisratio på 3:1 overvejes (det vil sige at en dosis af deferasirox filmovertrukne tabletter, der numerisk er en tredjedel af deferoxamindosis).
English: 28 dispersible tablets
Danish: 28 dispergible tabletter
English: In patients with moderate hepatic impairment (Child-Pugh Class B), the dose should be considerably reduced followed by progressive increase up to a limit of 50% (see sections 4.4 and 5.2), and EXJADE must be used with caution in such patients.
Danish: Hos patienter med moderat nedsat leverfunktion (Child-Pugh Class B) bør dosis reduceres betydeligt efterfulgt af gradvis dosisøgning op til en grænse på 50% (se pkt.
English: Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be lifethreatening or fatal, have been reported.
Danish: Der er blevet rapporteret alvorlige kutane bivirkninger (SCAR), herunder Stevens-Johnsons syndrom (SJS), toksisk epidermal nekrolyse (TEN) og lægemiddelreaktioner med eosinofili og systemiske symptomer (DRESS), som kan være livstruende eller dødelige.
English: For patients who are unable to swallow whole tablets, the film-coated tablets may be crushed and administered by sprinkling the full dose onto soft food, e.g. yogurt or apple sauce (pureed apple).
Danish: For patienter, som ikke er i stand til at sluge hele tabletter, kan filmovertrukne tabletter knuses og indtages ved at drysse hele dosen ud over blød mad, som fx yoghurt eller æblemos.
English: During clinical studies, dose-dependent increases in serum creatinine occurred in about 36% of patients, though most remained within the normal range.
Danish: Under kliniske studier med forekom dosisafhængige forhøjelser af serum-kreatinin hos omkring 36% af patienterne, selvom de fleste blev inden for normalområdet.
English: Taking EXJADE at the same time each day will also help you remember when to take your medicine.
Danish: Det vil også gøre det lettere for dig at huske, hvornår du skal tage din medicin.
English: Hepatic failure Skin and subcutaneous tissue disorders Common:
Danish: Hud og subkutane væv Almindelig:
English: • Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP.
Danish: • Brug ikke lægemidlet efter den udløbsdato, der står på blister og pakningen efter EXP og Udløbsdato.